<?xml version="1.0" encoding="UTF-8"?>
<span>The Cognitive Neuroscience Initiative focuses primarily on neurocognitive and psychophysiological functioning in individuals with schizophrenia and related disorders, using a wide range of specific assessment paradigms. Research programs in this Initiative are based on the premise that neurocognitive performance deficits and psychophysiological abnormalities are core, enduring aspects of these disorders that are critical to etiology, pathophysiology, and treatment. In terms of outcome, these deficits and abnormalities are viewed as critical for daily functioning of psychiatric patients. Research projects in this initiative include:
<li>A family genetic study of children with schizophrenia and attention deficit hyperactivity disorder
<li>Studies examining the neurobehavioral sequelae of traumatic brain injuries in children and adults
<li>Studies of fMRI and electrophysiology that explore the nature and neural basis of deficits in visual perception in patients with schizophrenia.
<li>Studies of the neurocognitive effects of novel drugs for schizophrenia
<li>A series of longitudinal studies on the key influences on symptomatic course, work functioning, and social relationships during the initial years after onset of schizophrenia
<li>Family studies to identify neurocognitive factors in genetic susceptibility to schizophrenia.
The Initiative includes three laboratories that form an extensive collaborative research network as well as coordinated training opportunities. Senior faculty includes: Drs. Robert Asarnow, Michael F. Green, and Keith H. Nuechterlein.